Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Not Recruiting

Trial ID: NCT04130438

Purpose

The proposed clinical trial is relevant to public health because it is expected to expand the differential diagnosis and provide an evidence--based therapy for the large population of patients with angina in the absence of obstructive CAD who currently remain undiagnosed and untreated. It, therefore, upholds an important part of the mission of the The National Heart, Lung, and Blood Institute (NHLBI), which is to promote the treatment of heart disease and enhance the health of all individuals so that they can live longer and more fulfilling lives.

Official Title

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Stanford Investigator(s)

Jennifer Tremmel
Jennifer Tremmel

Susan P. and Riley P. Bechtel Medical Director and Associate Professor of Medicine (Cardiovascular Medicine)

Eligibility

Inclusion Criteria

1. Age ≥18 years
2. Stable angina (typical or atypical, based on Diamond criteria (35))
3. Exercise stress echocardiogram or exercise stress test (with beta blocker or calcium channel blocker held) performed within six months of enrollment
4. CCTA or invasive coronary angiogram confirming the presence of an MB
5. Absence of obstructive CAD, as demonstrated by no ischemia on stress testing and no significant obstructive CAD (coronary stenosis \<50%) on CCTA or invasive coronary angiogram

Exclusion Criteria:

1. Asymptomatic
2. Status--post heart transplant
3. Presence of another likely explanation of chest pain, such as pulmonary hypertension, hypertrophic obstructive cardiomyopathy, or aortic stenosis
4. Presence of an acute coronary syndrome (unstable angina, NSTEMI, or STEMI), Tako--tsubo, or cardiogenic shock
5. An abnormal left ventricular ejection fraction (EF\<55%)
6. History of a severe adverse reaction to beta blockers or calcium channel blockers (prior minor intolerance or ineffectiveness not exclusion)
7. Use of existing medication that has an unsafe drug--drug interaction with beta blockers or calcium channel blockers
8. Refusal to take beta blockers or calcium channel blockers
9. Resting systolic blood pressure \<100 mmHg or heart rate \<50 beats per minute
10. Inability to provide an informed consent, including an inability to speak, read, or understand English or Spanish
11. A hearing impairment that won't allow for a typical verbal conversation or a visual impairment that won't allow for reading of the written consent
12. A potentially vulnerable subject (including pregnant women, prisoners, economically and educationally disadvantaged, decisionally impaired, and institutionalized individuals)

Intervention(s):

drug: Nebivolol

drug: Diltiazem

other: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jennifer A Tremmel, MD
650-723-0180